SpringWorks Therapeutics, Inc.

NasdaqGS:SWTX Stok Raporu

Piyasa değeri: US$2.3b

SpringWorks Therapeutics Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

SpringWorks Therapeutics şirketinin kazançları yıllık ortalama -41.1% oranında azalırken, Biotechs sektörünün kazançları yıllık 19% oranında artan oldu. Gelirler yıllık ortalama 33.6% oranında artan oldu.

Anahtar bilgiler

-41.1%

Kazanç büyüme oranı

32.9%

EPS büyüme oranı

Biotechs Sektör Büyümesi17.0%
Gelir büyüme oranı33.6%
Özkaynak getirisi-54.1%
Net Marj-349.3%
Sonraki Kazanç Güncellemesi12 Nov 2024

Yakın geçmiş performans güncellemeleri

Recent updates

SpringWorks Therapeutics Merits A Speculative Buy

Nov 04

SpringWorks Therapeutics: Rising On A Strong Post-Launch Quarter, Now Justified As A Buy

Aug 07

Need To Know: Analysts Are Much More Bullish On SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Revenues

May 11
Need To Know: Analysts Are Much More Bullish On SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Revenues

We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

May 03
We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

SpringWorks Therapeutics: Newly Commercial Stage, Fully Valued Biotech Means Steer Clear

Apr 25

SpringWorks Therapeutics: Multiple Opportunities, But No Sure-Fire Winners

Apr 19

We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

Sep 20
We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

We're Not Very Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Rate

Jun 07
We're Not Very Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Rate

We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

Feb 22
We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation

Nov 09
Here's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation

SpringWorks drops 21% as Allogene drops lead asset in combination study

Aug 10

SpringWorks Therapeutics GAAP EPS of -$1.41 misses by $0.15

Aug 04

Sizing Up SpringWorks Therapeutics

Jul 20

Will SpringWorks Therapeutics (NASDAQ:SWTX) Spend Its Cash Wisely?

Jun 06
Will SpringWorks Therapeutics (NASDAQ:SWTX) Spend Its Cash Wisely?

SpringWorks Therapeutics: Rating Buy Ahead Of Mid-Year Data Releases

May 02

Companies Like SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Invest In Growth

Dec 30
Companies Like SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Invest In Growth

SpringWorks Is A Biotech To Watch With Several Partnerships And Solid Drug Pipeline

Dec 14

SpringWorks Therapeutics (NASDAQ:SWTX) Is In A Strong Position To Grow Its Business

Sep 15
SpringWorks Therapeutics (NASDAQ:SWTX) Is In A Strong Position To Grow Its Business

SpringWorks shows durable effect for neurofibroma therapy with long-term data

Jun 15

SpringWorks teams up with Seagen to evaluate nirogacestat combo in multiple myeloma

Jun 07

We're Interested To See How SpringWorks Therapeutics (NASDAQ:SWTX) Uses Its Cash Hoard To Grow

May 31
We're Interested To See How SpringWorks Therapeutics (NASDAQ:SWTX) Uses Its Cash Hoard To Grow

SpringWorks Therapeutics EPS misses by $0.11

May 06

Gelir ve Gider Dağılımı

SpringWorks Therapeutics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

NasdaqGS:SWTX Gelir, gider ve kazançlar (USD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Jun 2486-301224179
31 Mar 2426-339213171
31 Dec 235-325198150
30 Sep 230-305178145
30 Jun 230-298167143
31 Mar 230-289151146
31 Dec 220-277135146
30 Sep 220-259120138
30 Jun 220-228103124
31 Mar 220-20687118
31 Dec 210-17472102
30 Sep 2135-1075488
30 Jun 2135-874379
31 Mar 2135-603560
31 Dec 2035-462952
30 Sep 200-732649
30 Jun 200-682346
31 Mar 200-622044
31 Dec 190-511743
30 Sep 190-411434
30 Jun 190-291127
31 Mar 190-181017
31 Dec 180-18910

Kaliteli Kazançlar: SWTX şu anda kârlı değil.

Büyüyen Kar Marjı: SWTX şu anda kârlı değil.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: SWTX kârlı değildir ve zararlar son 5 yılda yılda 41.1% oranında artmıştır.

Büyüme Hızlandırma: SWTX 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: SWTX kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( -2.3% ) karşılaştırılması zorlaşıyor.


Özkaynak Getirisi

Yüksek ROE: SWTX hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -54.08% ) sahiptir.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin